Study guide

5.2 Ultrasound-Enhancing Agents and LV Opacification

CCI Registered Cardiac Sonographer RCS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: RCS Orientation and Clinical Context

1.1 RCS Identity, Exam Format, Application, and Retesting 1.2 Clinical History, Symptoms, Indications, and Risk Factors 1.3 Prior Studies, Serial Change, and Cross-Modality Context

2 Chapter 2: Orders, Safety, and Patient Preparation

2.1 Order Verification, Scope, and Protocol Selection 2.2 Sonographer Ergonomics and Staff Safety 2.3 Patient Preparation, Positioning, Consent, Infection Control, and Aftercare

3 Chapter 3: Reporting and 2-D TTE Foundations

3.1 Structured Findings, Significant Results, and Escalation 3.2 Standard 2-D TTE Windows, Views, and Acquisition Sequence 3.3 2-D Measurements, Foreshortening, Image Quality, and QA

4 Chapter 4: M-Mode and Doppler Acquisition

4.1 M-Mode Alignment, Timing, Measurements, and Pitfalls 4.2 Color Doppler Acquisition, Scale, Gain, and Jet Display 4.3 PW and CW Spectral Doppler Acquisition

5 Chapter 5: Advanced Doppler and Contrast

5.1 Tissue Doppler and Hemodynamic Sample Placement 5.2 Ultrasound-Enhancing Agents and LV Opacification 5.3 Agitated-Saline Studies and Intracardiac Shunts

6 Chapter 6: Stress Echocardiography

6.1 Exercise Stress Echo Protocols and Peak Imaging 6.2 Pharmacologic Stress Echo, Dobutamine, and Safety 6.3 Non-Ischemic Stress Echo and Hemodynamic Provocation

7 Chapter 7: TEE, Strain, and 3-D TEE

7.1 Assisting TEE: Preparation, Probe Safety, Views, and Complications 7.2 Strain Acquisition, Tracking Quality, and Reproducibility 7.3 3-D TEE Acquisition, Cropping, Orientation, and Artifacts

8 Chapter 8: 3-D TTE and the Aortic Valve

8.1 3-D TTE Full-Volume Acquisition and Quantitation 8.2 Aortic-Valve Anatomy, Morphology, and Function 8.3 Aortic Stenosis: Velocities, Gradients, Valve Area, and Flow States

9 Chapter 9: Aortic Regurgitation and Mitral Structure

9.1 Aortic Regurgitation Mechanisms and Integrated Severity 9.2 Mitral-Valve Anatomy, Motion, and Mechanisms 9.3 Mitral Stenosis: Planimetry, Gradients, Pressure Half-Time, and Suitability

10 Chapter 10: Mitral and Tricuspid Valve Findings

10.1 Mitral Regurgitation Mechanism, Quantitation, and Severity Integration 10.2 Tricuspid-Valve Anatomy, Structure, and Function 10.3 Tricuspid Stenosis Assessment

11 Chapter 11: Right-Sided Valve Disease

11.1 Tricuspid Regurgitation Mechanism and Severity 11.2 Pulmonic-Valve Anatomy, Structure, and Function 11.3 Pulmonic Stenosis Assessment

12 Chapter 12: Pulmonic Regurgitation and Prosthetic Valves

12.1 Pulmonic Regurgitation Mechanism and Severity 12.2 Normal Mechanical and Bioprosthetic Valve Assessment 12.3 Prosthetic Obstruction, Regurgitation, Thrombosis, and Patient–Prosthesis Mismatch

13 Chapter 13: Endocarditis and Cardiac Chambers

13.1 Valvular Endocarditis, Vegetations, Abscess, and Complications 13.2 LV and LA Size, Geometry, Volumes, Mass, and Function 13.3 RV and RA Size, Pressure, Volume, and Function

14 Chapter 14: Cardiomyopathy Phenotypes and Diastology

14.1 Dilated and Hypertrophic Cardiomyopathies, SAM, and LVOT Obstruction 14.2 Restrictive, Arrhythmogenic, and Stress Cardiomyopathies 14.3 Diastolic Function, Filling Pressure, Grading, and Pitfalls

15 Chapter 15: Systolic Function and Ischemia

15.1 LV Systolic Function, Simpson EF, Regional Motion, and Output 15.2 RV Systolic Function: TAPSE, S-prime, FAC, and Coupling 15.3 Ischemic Heart Disease, Coronary Territories, Stress Response, and Complications

16 Chapter 16: Pericardium and Great Vessels

16.1 Pericardial Effusion, Tamponade, Constriction, and Doppler Physiology 16.2 Great Vessels, Venous Return, and Pulmonary Artery Assessment 16.3 Aortic Root, Aneurysm, Dissection, and Coarctation

17 Chapter 17: Pulmonary Pressure, Masses, and Congenital Recognition

17.1 Pulmonary Hypertension, RAP/PASP Estimation, and RV Consequences 17.2 Cardiac Masses, Thrombus, Tumor, Vegetation, and Mimics 17.3 Adult Recognition of ASD, VSD, PFO, PDA, and Congenital Clues

18 Chapter 18: Devices, Strain, and Hemodynamics

18.1 ICDs, Pacemakers, Occluders, Closure Devices, and Mechanical Support 18.2 Strain Interpretation, Global Longitudinal Strain, and Disease Patterns 18.3 Cardiac Hemodynamics, Bernoulli, Continuity, Stroke Volume, and Shunts

19 Chapter 19: Infiltrative Disease and Physics Foundations

19.1 Amyloid, Sarcoid, and Other Infiltrative Disease Patterns 19.2 Ultrasound Wave Properties, Propagation, Frequency, and Wavelength 19.3 Artifact Recognition: Reverberation, Shadowing, Mirror, Refraction, and Aliasing

20 Chapter 20: Resolution and Doppler Optimization

20.1 Axial/Lateral Resolution, Frame Rate, Depth, Focus, and Trade-Offs 20.2 Spectral Doppler Optimization, Nyquist, Filters, Gain, and Angle 20.3 Color Doppler Optimization, Scale, Priority, Variance, and Gain

21 Chapter 21: 2-D, 3-D, and Contrast Optimization

21.1 2-D Optimization: Frequency, Gain, TGC, Harmonics, Depth, and Focus 21.2 3-D Optimization: Volume Rate, Stitching, Cropping, and Display 21.3 Contrast Optimization: Mechanical Index, Destruction, Replenishment, and Artifacts

5.2 Ultrasound-Enhancing Agents and LV Opacification

Key Takeaways Explain This Topic AI

Commercial UEAs traverse the pulmonary circulation to opacify the LV and improve endocardial-border definition; they are not agitated-saline shunt contrast.

UEA enhancement is recommended when two or more contiguous LV segments remain inadequately seen for function or regional wall-motion analysis.

Screen and administer by the selected product's current label, authorized scope, and local protocol, with emergency readiness for uncommon serious reactions.

Low-MI contrast-specific imaging, coordinated delivery, and correction of attenuation or destruction produce diagnostic borders without excessive microbubble concentration.

Last updated: July 2026

Commercial UEAs cross the pulmonary circulation

An injectable ultrasound-enhancing agent, or UEA, contains gas-filled microspheres designed to survive pulmonary transit and enhance the blood pool. In echocardiography, commercial UEAs are used with contrast-specific imaging to opacify the left ventricular cavity and delineate the endocardial border. They are not radiographic iodinated dye, and they are not the hand-agitated saline-air mixture used primarily to test right-to-left shunting. The products have different shells, gases, preparation steps, doses, ingredients, and labels; never treat UEA as one interchangeable drug.

ASE recommends UEA use in a routine resting study when two or more contiguous LV segments cannot be adequately visualized for assessment of ejection fraction or regional wall motion. UEA can also improve reproducibility of LV volumes and function when accurate quantification is clinically important and can help define apical morphology, aneurysm, or suspected thrombus within an appropriate protocol. It cannot create an acoustic window when the heart is not reachable because lung or chest anatomy blocks transmission. Acquire optimized native images first, then identify the specific unanswered question.

Phase Essential actions Frequent failure

Before administration Verify patient, order or protocol, indication, agent, current label, hypersensitivity history, IV patency, authority, and emergency readiness Calling all contrast allergies equivalent or relying on an old blanket contraindication list

Initial imaging Save native loops, activate the system's UEA or low-MI preset, minimize unnecessary depth and sector width Using ordinary high-MI harmonic imaging that destroys microspheres

Delivery Prepare and administer the exact agent by its label and local policy; coordinate injection or infusion with imaging Improvising dose, flush, route, or vial handling from another product

Optimization Seek uniform cavity opacification and a crisp border without near-field destruction or basal attenuation Adding more agent whenever the image is poor, even when concentration is already excessive

After administration Monitor as the label and policy require, recognize symptoms, document dose and response, and discard materials correctly Leaving before a reaction is assessed or failing to record the administered product

Safety language must stay current and agent specific

Known or suspected hypersensitivity to the selected microsphere or its components is a central contraindication in current U.S. labels. Some lipid products contain polyethylene glycol, while an albumin-shelled product has different allergy considerations. Ask about the ingredients relevant to the agent being used, not simply shellfish or iodine. Current labels warn that serious cardiopulmonary or hypersensitivity reactions can occur, commonly during or soon after administration, so trained personnel and resuscitation equipment must be available and the patient monitored according to the label and facility policy.

Do not repeat obsolete rules. ASE's 2018 update states that pulmonary hypertension and right-to-left shunts are not blanket contraindications to all UEAs. Current labels instead require product-specific assessment and may warn about systemic embolization when microspheres bypass lung filtration. UEAs are intravenous agents and must not be injected into an arterial line. Pregnancy, pediatrics, sickle cell disease, unstable cardiopulmonary conditions, and other special populations require the current selected-agent label and local medical decision; one product's precaution cannot be generalized to every agent.

Administration by a sonographer depends on education, competency, licensure, authorized scope, and institutional policy. Verify a functioning venous route and never assume an unlabeled catheter is venous. Follow required independent checks and aseptic technique. Explain that the agent improves the ultrasound image and ask the patient to report dyspnea, throat tightness, rash, flushing, chest or back pain, dizziness, or other new symptoms. If a reaction is suspected, stop administration, assess the patient, call for help, initiate the emergency protocol within training, preserve vital information, and document objectively. Do not diagnose the reaction casually or continue imaging merely to finish the protocol.

Optimize the microbubble image

Contrast-specific very-low-mechanical-index imaging preserves microspheres while suppressing tissue signal. Start with the manufacturer's cardiac LVO preset and adjust depth, focus, frequency, gain, and dynamic range for the patient. Save nonforeshortened A4C, A2C, and apical long-axis loops with complete borders. Verify automated tracings against the enhanced blood-tissue interface; papillary muscles and trabeculations follow the same chamber-tracing convention used in native images.

Too high a microsphere concentration causes basal attenuation and shadowing, hiding the very border the agent should reveal. A forceful bolus may create apical swirling or near-field destruction. Correct the delivery and imaging interaction: pause for concentration to fall, use the label-supported slower flush or infusion strategy, lower destructive output, or adjust the protocol. Do not increase gain until noise becomes a false endocardium. A brief high-MI flash may be used under an approved protocol to clear microspheres, followed by low-MI replenishment imaging; continuous high output destroys contrast and current labels warn about arrhythmia risk at high MI.

The endpoint is diagnostic information, not maximum brightness. The cavity should fill homogeneously, myocardium should remain distinguishable, the apex should be visible without foreshortening, and basal segments should not disappear behind attenuation. If a suspected apical thrombus remains, use multiple views and observe whether the filling defect persists against an opacified cavity; near-field artifact, trabeculation, and poor mixing can mimic a mass. The sonographer documents appearance and limitations for physician interpretation rather than declaring thrombus or excluding it from one imperfect loop.

Commercial UEA and agitated saline can both look like bubbles on a monitor, but their destinations answer different questions. UEA intentionally traverses the lungs to enhance the left heart. Agitated saline should densely opacify the right heart and ordinarily be filtered by normal pulmonary capillaries; left-heart appearance is analyzed for a shunt. Selecting the wrong method can produce a technically successful injection that cannot answer the indication.

Read the selected-agent label

Contraindications, ingredients, preparation, dose, route, monitoring, and special-population warnings are product specific and change over time. Current institutional policy and the live prescribing information control.